Natalie Danziger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8446240/publications.pdf

Version: 2024-02-01

		933447	940533
60	342	10	16
papers	citations	h-index	g-index

60	60	60	536
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).. Journal of Clinical Oncology, 2022, 40, 604-604.	1.6	1
2	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.. Journal of Clinical Oncology, 2022, 40, 474-474.	1.6	0
3	Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).. Journal of Clinical Oncology, 2022, 40, 550-550.	1.6	0
4	Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 156-156.	1.6	0
5	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	0
6	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.. Journal of Clinical Oncology, 2022, 40, 164-164.	1.6	0
7	Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD). Cancer Research, 2022, 82, PD14-09-PD14-09.	0.9	1
8	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 292-292.	1.6	0
9	Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.. Journal of Clinical Oncology, 2022, 40, 5596-5596.	1.6	0
10	Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2022, 40, 4568-4568.	1.6	2
11	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 4550-4550.	1.6	0
12	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precision Oncology, 2022, , .	3.0	10
13	Targetable genomic mutations in young women with advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, 1027-1027.	1.6	0
14	Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.. Journal of Clinical Oncology, 2022, 40, 4156-4156.	1.6	1
15	Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 5063-5063.	1.6	1
16	Landscape of homologous recombination reversion mutations in gynecologic malignancies.. Journal of Clinical Oncology, 2022, 40, 5576-5576.	1.6	1
17	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, e16535-e16535.	1.6	0
18	Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. Journal of the American Academy of Dermatology, 2021, 84, 1069-1071.	1.2	5

#	Article	IF	Citations
19	Clinicopathologic, genomic and protein expression characterization of 356 <scp>ROS1</scp> fusion driven solid tumors cases. International Journal of Cancer, 2021, 148, 1778-1788.	5.1	14
20	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Medicine, 2021, 10, 53-61.	2.8	39
21	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Modern Pathology, 2021, 34, 252-263.	5.5	78
22	In search of novel synthetic lethality anti-cancer drug targets in intrahepatic cholangiocarcinoma: MTAP genomic loss.. Journal of Clinical Oncology, 2021, 39, 337-337.	1.6	0
23	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances, 2021, 3, vdab017.	0.7	6
24	Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 165-165.	1.6	2
25	Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. JTO Clinical and Research Reports, 2021, 2, 100100.	1.1	8
26	HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.. Journal of Clinical Oncology, 2021, 39, 163-163.	1.6	0
27	Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).. Journal of Clinical Oncology, 2021, 39, 485-485.	1.6	1
28	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Modern Pathology, 2021, 34, 1425-1433.	5.5	19
29	Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 2-2.	1.6	2
30	HPV-16 positive clinically advanced squamous cell carcinoma of the urinary bladder (mBSCC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 481-481.	1.6	0
31	Sarcomatoid (srcRCC) versus clear cell (ccRCC) renal cell carcinoma: A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 349-349.	1.6	2
32	Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2021, 39, 388-388.	1.6	0
33	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Pathology and Oncology Research, 2021, 27, 592997.	1.9	11
34	Genomic landscape of MSH6-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	1.6	1
35	Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.. Journal of Clinical Oncology, 2021, 39, 9116-9116.	1.6	0
36	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 3130-3130.	1.6	1

#	Article	IF	Citations
37	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	1.6	0
38	IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.. Journal of Clinical Oncology, 2021, 39, 4009-4009.	1.6	11
39	Comprehensive genomic profiling (CGP) of 275 male breast cancer (BC) tissue (TBx) and liquid (LBx) biopsies: Comparative analysis to a female cohort (FBC) and therapeutic considerations.. Journal of Clinical Oncology, 2021, 39, 539-539.	1.6	0
40	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	3.7	16
41	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. JCO Precision Oncology, 2021, 5, 1013-1023.	3.0	3
42	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	3.7	9
43	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564.	4.1	5
44	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e1-731.e15.	1.6	7
45	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Oncologist, 2020, 25, 943-953.	3.7	19
46	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. Frontiers in Neurology, 2020, 11, 544680.	2.4	16
47	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPVâ€“ Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. JCO Precision Oncology, 2020, 4, 647-661.	3.0	21
48	Differential genomic landscape of clinically advanced/metastatic chordomas (mChor) based on primary tumor site.. Journal of Clinical Oncology, 2020, 38, 11521-11521.	1.6	3
49	Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 4579-4579.	1.6	1
50	Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).. Journal of Clinical Oncology, 2020, 38, 5534-5534.	1.6	0
51	Patient-matched tissue and liquid biopsies identify shared and acquired genomic alterations in breast cancer.. Journal of Clinical Oncology, 2020, 38, 1050-1050.	1.6	15
52	Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1053-1053.	1.6	0
53	Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.. Journal of Clinical Oncology, 2020, 38, 3622-3622.	1.6	1
54	Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 11541-11541.	1.6	0

#	Article	IF	Citations
55	Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 5066-5066.	1.6	0
56	Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2020, 38, e17053-e17053.	1.6	2
57	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. Journal of Clinical Oncology, 2020, 38, 5087-5087.	1.6	1
58	Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 3558-3558.	1.6	1
59	Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations. Blood, 2019, 134, 2541-2541.	1.4	2
60	Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA. Blood, 2019, 134, 4659-4659.	1.4	3